Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12614703 | 0.87 | ALDH1A1 (0.48) | HSD11B1ALDH1A1RAB9AKMT2AACHE | |
| SCHEMBL27981545 | 0.85 | MAPT (0.58) | HSD11B1ALDH1A1RAB9AKMT2AACHE | |
| SCHEMBL1792783 | 0.85 | MAPT (0.58) | HSD11B1ALDH1A1RAB9AKMT2AACHE | |
| SCHEMBL6081340 | 0.84 | USP2 (0.55) | HSD11B1ALDH1A1RAB9AKMT2AACHE | |
| SCHEMBL1790581 | 0.83 | MAPT (0.58) | HSD11B1ALDH1A1RAB9AKMT2AACHE | |
| SCHEMBL1571372 | 0.83 | ALDH1A1 (0.68) | ALDH1A1RAB9AKMT2AACHEMAPT | |
| SCHEMBL12614112 | 0.83 | TRPA1 (0.55) | ALDH1A1RAB9AKMT2AACHEMAPT | |
| SCHEMBL1792200 | 0.82 | ALDH1A1 (0.71) | ALDH1A1RAB9AKMT2AACHEMAPT | |
| SCHEMBL31173291 | 0.82 | ALDH1A1 (0.71) | ALDH1A1RAB9AKMT2AACHEMAPT | |
| SCHEMBL28547385 | 0.78 | FAAH (0.48) | ALDH1A1RAB9AKMT2AMAPTMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112608269-B | Method for catalytically synthesizing pyrrolidine by weak interaction of chalcogen | 山东大学 | 2022-05-06 | — | — | CN | disclosed |
| CN-112608269-A | Method for catalytically synthesizing pyrrolidine by weak interaction of chalcogen | 山东大学 | 2021-04-06 | — | — | CN | disclosed |
| US-20110112288-A1 | Metal Porphyrin Catalyzed Olefin Aziridination with Sulfonyl Azides | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112288-A1 | Metal Porphyrin Catalyzed Olefin Aziridination with Sulfonyl Azides | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112288-A1 | Metal Porphyrin Catalyzed Olefin Aziridination with Sulfonyl Azides | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2009146032-A2 | METAL PORPHYRIN CATALYZED OLEFIN AZIRIDINATION WITH SULFONYL AZIDES | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112288-A1 | Metal Porphyrin Catalyzed Olefin Aziridination with Sulfonyl Azides | PPOX, SOD1, AP1S1 | HSD11B1 3404/4885ALDH1A1 1473/4885RAB9A 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.